Hypertrophic Cardiomyopathy in the Era of Genomic Medicine

Johan Martijn Bos, Michael John Ackerman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hypertrophic cardiomyopathy (HCM) is a relatively common, primary disorder of the myocardium characterized by unexplained left ventricular hypertrophy affecting perhaps as many as 1 in 500 people. HCM is underscored by profound phenotypic and genotypic heterogeneity, with currently more than 20 genes associated with HCM. The underlying genetic mechanism for approximately 30%-60% of HCM remains elusive. Although many genotype-phenotype relationships have been observed, only a few carry enough clinical significance to aid physicians predicting genotype, course, and prognosis of the disease. Current treatment for HCM is aimed at symptom relief, but (animal) studies and clinical trials are underway to test (genotype-specific) pharmacologic treatments for prevention or regression of cardiac hypertrophy. This chapter details the clinical presentation of HCM, its genetic and nongenetic predisposition, important genotype-phenotype relationships, implications for genetic counseling and family screening, and treatment options for the disease.

Original languageEnglish (US)
Title of host publicationGenomic and Precision Medicine
Subtitle of host publicationCardiovascular Disease: Third Edition
PublisherElsevier Inc.
Pages103-126
Number of pages24
ISBN (Print)9780128018125
DOIs
StatePublished - Nov 13 2017

Fingerprint

Hypertrophic Cardiomyopathy
Medicine
Genotype
Screening
Animals
Genes
Phenotype
Genetic Counseling
Cardiomegaly
Left Ventricular Hypertrophy
Genetic Predisposition to Disease
Myocardium
Therapeutics
Clinical Trials
Physicians

Keywords

  • Beta-myosin heavy chain (MYH7)
  • Echocardiography
  • Genetic testing
  • Genetics
  • Hypertrophic cardiomyopathy (HCM)
  • Hypertrophy
  • Left ventricular hypertrophy (LVH)
  • Myofilament
  • Myosin binding protein C (MYBPC3)
  • Sarcomere
  • Sudden cardiac death (SCD)
  • Whole exome sequencing (WES)

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bos, J. M., & Ackerman, M. J. (2017). Hypertrophic Cardiomyopathy in the Era of Genomic Medicine. In Genomic and Precision Medicine: Cardiovascular Disease: Third Edition (pp. 103-126). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-801812-5.00005-6

Hypertrophic Cardiomyopathy in the Era of Genomic Medicine. / Bos, Johan Martijn; Ackerman, Michael John.

Genomic and Precision Medicine: Cardiovascular Disease: Third Edition. Elsevier Inc., 2017. p. 103-126.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bos, JM & Ackerman, MJ 2017, Hypertrophic Cardiomyopathy in the Era of Genomic Medicine. in Genomic and Precision Medicine: Cardiovascular Disease: Third Edition. Elsevier Inc., pp. 103-126. https://doi.org/10.1016/B978-0-12-801812-5.00005-6
Bos JM, Ackerman MJ. Hypertrophic Cardiomyopathy in the Era of Genomic Medicine. In Genomic and Precision Medicine: Cardiovascular Disease: Third Edition. Elsevier Inc. 2017. p. 103-126 https://doi.org/10.1016/B978-0-12-801812-5.00005-6
Bos, Johan Martijn ; Ackerman, Michael John. / Hypertrophic Cardiomyopathy in the Era of Genomic Medicine. Genomic and Precision Medicine: Cardiovascular Disease: Third Edition. Elsevier Inc., 2017. pp. 103-126
@inbook{25e130bdd0bf40e7b49d6f786f97093e,
title = "Hypertrophic Cardiomyopathy in the Era of Genomic Medicine",
abstract = "Hypertrophic cardiomyopathy (HCM) is a relatively common, primary disorder of the myocardium characterized by unexplained left ventricular hypertrophy affecting perhaps as many as 1 in 500 people. HCM is underscored by profound phenotypic and genotypic heterogeneity, with currently more than 20 genes associated with HCM. The underlying genetic mechanism for approximately 30{\%}-60{\%} of HCM remains elusive. Although many genotype-phenotype relationships have been observed, only a few carry enough clinical significance to aid physicians predicting genotype, course, and prognosis of the disease. Current treatment for HCM is aimed at symptom relief, but (animal) studies and clinical trials are underway to test (genotype-specific) pharmacologic treatments for prevention or regression of cardiac hypertrophy. This chapter details the clinical presentation of HCM, its genetic and nongenetic predisposition, important genotype-phenotype relationships, implications for genetic counseling and family screening, and treatment options for the disease.",
keywords = "Beta-myosin heavy chain (MYH7), Echocardiography, Genetic testing, Genetics, Hypertrophic cardiomyopathy (HCM), Hypertrophy, Left ventricular hypertrophy (LVH), Myofilament, Myosin binding protein C (MYBPC3), Sarcomere, Sudden cardiac death (SCD), Whole exome sequencing (WES)",
author = "Bos, {Johan Martijn} and Ackerman, {Michael John}",
year = "2017",
month = "11",
day = "13",
doi = "10.1016/B978-0-12-801812-5.00005-6",
language = "English (US)",
isbn = "9780128018125",
pages = "103--126",
booktitle = "Genomic and Precision Medicine",
publisher = "Elsevier Inc.",
address = "United States",

}

TY - CHAP

T1 - Hypertrophic Cardiomyopathy in the Era of Genomic Medicine

AU - Bos, Johan Martijn

AU - Ackerman, Michael John

PY - 2017/11/13

Y1 - 2017/11/13

N2 - Hypertrophic cardiomyopathy (HCM) is a relatively common, primary disorder of the myocardium characterized by unexplained left ventricular hypertrophy affecting perhaps as many as 1 in 500 people. HCM is underscored by profound phenotypic and genotypic heterogeneity, with currently more than 20 genes associated with HCM. The underlying genetic mechanism for approximately 30%-60% of HCM remains elusive. Although many genotype-phenotype relationships have been observed, only a few carry enough clinical significance to aid physicians predicting genotype, course, and prognosis of the disease. Current treatment for HCM is aimed at symptom relief, but (animal) studies and clinical trials are underway to test (genotype-specific) pharmacologic treatments for prevention or regression of cardiac hypertrophy. This chapter details the clinical presentation of HCM, its genetic and nongenetic predisposition, important genotype-phenotype relationships, implications for genetic counseling and family screening, and treatment options for the disease.

AB - Hypertrophic cardiomyopathy (HCM) is a relatively common, primary disorder of the myocardium characterized by unexplained left ventricular hypertrophy affecting perhaps as many as 1 in 500 people. HCM is underscored by profound phenotypic and genotypic heterogeneity, with currently more than 20 genes associated with HCM. The underlying genetic mechanism for approximately 30%-60% of HCM remains elusive. Although many genotype-phenotype relationships have been observed, only a few carry enough clinical significance to aid physicians predicting genotype, course, and prognosis of the disease. Current treatment for HCM is aimed at symptom relief, but (animal) studies and clinical trials are underway to test (genotype-specific) pharmacologic treatments for prevention or regression of cardiac hypertrophy. This chapter details the clinical presentation of HCM, its genetic and nongenetic predisposition, important genotype-phenotype relationships, implications for genetic counseling and family screening, and treatment options for the disease.

KW - Beta-myosin heavy chain (MYH7)

KW - Echocardiography

KW - Genetic testing

KW - Genetics

KW - Hypertrophic cardiomyopathy (HCM)

KW - Hypertrophy

KW - Left ventricular hypertrophy (LVH)

KW - Myofilament

KW - Myosin binding protein C (MYBPC3)

KW - Sarcomere

KW - Sudden cardiac death (SCD)

KW - Whole exome sequencing (WES)

UR - http://www.scopus.com/inward/record.url?scp=85042522681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042522681&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801812-5.00005-6

DO - 10.1016/B978-0-12-801812-5.00005-6

M3 - Chapter

SN - 9780128018125

SP - 103

EP - 126

BT - Genomic and Precision Medicine

PB - Elsevier Inc.

ER -